Overview

A Study of Safety and Effectiveness of NovoThirteen® (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan

Status:
Enrolling by invitation
Trial end date:
2024-09-30
Target enrollment:
0
Participant gender:
All
Summary
This study is conducted in Asia. Tha aim of this study is to investigate Safety and Effectiveness of NovoThirteen® (rFXIII) during treatment of congenital FXIII deficiency in Japan.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Novo Nordisk A/S
Criteria
Inclusion Criteria:

- Male of female patients, regardless of age, requiring treatment with NovoThirteenR for
whom the treating physician has decided to use NovoThirteenR (rFXIII) treatment